{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-127117","form_type":"8-K","ticker":"QURE","cik":"0001590560","company_name":"uniQure N.V.","filed_at":"2023-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.671132+00:00","generated_at":"2026-06-07T10:34:06.519351+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"uniQure AMT-130 shows dose-dependent clinical benefit in Huntington's; NfL below baseline at 30 months","bullets":["AMT-130 showed favorable cUHDRS difference of 0.39 (low-dose at 30 months) and 1.24 (high-dose at 18 months) vs natural history.","Mean CSF NfL low-dose cohort 6.6% below baseline at 30 months; high-dose cohort near baseline at 18 months.","AMT-130 generally well-tolerated; 4 AMT-130-related SAEs (CNS inflammation) in high-dose cohort managed with steroids.","Company plans regulatory interactions in Q1 2024 and next clinical update mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-127117","json":"https://secwatch.observer/filing/0001104659-23-127117.json","markdown":"https://secwatch.observer/filing/0001104659-23-127117.md","text":"https://secwatch.observer/filing/0001104659-23-127117.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590560/000110465923127117/0001104659-23-127117-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590560/000110465923127117/tm2333072d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T10:34:06.519351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}